|
gptkbp:instanceOf
|
gptkb:mood_stabilizer
gptkb:drug
gptkb:anticonvulsant
|
|
gptkbp:approvedInUS
|
1968
|
|
gptkbp:ATCCode
|
gptkb:N03AF01
|
|
gptkbp:brand
|
gptkb:Tegretol
gptkb:Carbatrol
gptkb:Epitol
gptkb:Equetro
|
|
gptkbp:CASNumber
|
298-46-4
|
|
gptkbp:category
|
antimanic agent
tricyclic compound
|
|
gptkbp:chemicalFormula
|
C15H12N2O
|
|
gptkbp:contraindication
|
history of bone marrow depression
hypersensitivity to tricyclic compounds
|
|
gptkbp:discoveredBy
|
gptkb:Walter_Schindler
|
|
gptkbp:discoveredIn
|
1953
|
|
gptkbp:eliminationHalfLife
|
12–17 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasBoxedWarning
|
aplastic anemia and agranulocytosis
serious dermatologic reactions
|
|
gptkbp:interactsWith
|
gptkb:milk
gptkb:phenytoin
gptkb:warfarin
gptkb:valproic_acid
gptkb:erythromycin
oral contraceptives
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
|
|
gptkbp:MeSH_ID
|
D002220
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
236.27 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL108
2554
DB00564
CHEBI:3380
|
|
gptkbp:riskFactor
|
HLA-B*1502 allele (increased risk of SJS in Asians)
|
|
gptkbp:routeOfAdministration
|
oral
rectal
|
|
gptkbp:seriousAdverseEffect
|
gptkb:Stevens-Johnson_syndrome
aplastic anemia
agranulocytosis
|
|
gptkbp:sideEffect
|
nausea
vomiting
dizziness
rash
drowsiness
hyponatremia
|
|
gptkbp:UNII
|
33CM23913M
|
|
gptkbp:usedFor
|
gptkb:peripheral_neuropathy
gptkb:trigeminal_neuralgia
bipolar disorder
epilepsy
|
|
gptkbp:bfsParent
|
gptkb:valproic_acid
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
carbamazepine
|